Mixed-Effects Modeling of Clinical DCE-MRI Data: Application to Colorectal Liver Metastases Treated With Bevacizumab

被引:9
|
作者
Ferl, Gregory Z. [1 ]
O'Connor, James P. B. [2 ]
Parker, Geoffrey J. M. [2 ]
Carano, Richard A. D. [3 ]
Acharya, Shiv J. [4 ]
Jayson, Gordon C. [5 ]
Port, Ruediger E. [1 ]
机构
[1] Genentech Inc, Dept Pharmacokinet & Pharmacodynam, San Francisco, CA 94080 USA
[2] Univ Manchester, Ctr Imaging Sci, Manchester, Lancs, England
[3] Genentech Inc, Biomed Imaging Dept, San Francisco, CA 94080 USA
[4] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA
[5] Christie Hosp, Dept Med Oncol, Manchester, Lancs, England
关键词
DCE-MRI; biomarker; bevacizumab; colorectal liver metastases; CONTRAST-ENHANCED MRI; KINETIC-ANALYSIS; PHARMACOKINETICS; INHIBITOR; AZD2171; TRACER; TRIALS;
D O I
10.1002/jmri.24514
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeMost dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data are evaluated for individual patients with cohorts analyzed to detect significant changes from baseline values, repeating the process at each posttreatment timepoint. Our study aimed to develop a statistically valid model for the complete time course of DCE-MRI data in a patient cohort. Materials and MethodsData from 10 patients with colorectal cancer liver metastases were analyzed, including two baseline scans and four post-bevacizumab scans. Apparent changes in tumor median K-trans were adjusted for changes in observed enhancing tumor fraction (EnF) by multiplying K-trans by EnF (KEnF). A mixed-effects model (MEM) was defined to describe the KEnF time course for all patients simultaneously by assuming a three-parameter indirect response model with model parameters lognormally distributed across patients. ResultsThe typical cohort time course showed a KEnF reduction to 59% of baseline at 24 hours, returning to 65% of baseline values by day 12. Interpatient variability of model parameters ranged from 11% to 307%. ConclusionThe MEM approach has potential for comparing responses at a group level in clinical trials with different doses, schedules, or combination regimens. Furthermore, the KEnF biomarker successfully resolved confounds in interpreting K-trans arising from therapy induced changes in the volume of enhancing tumor. J. Magn. Reson. Imaging 2015;41:132-141. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 21 条
  • [1] An Automated Method for Nonparametric Kinetic Analysis of Clinical DCE-MRI Data: Application to Glioblastoma Treated with Bevacizumab
    Ferl, Gregory Z.
    Xu, Lu
    Friesenhahn, Michel
    Bernstein, Lisa J.
    Barboriak, Daniel P.
    Port, Ruediger E.
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2010, 63 (05) : 1366 - 1375
  • [2] Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
    De Bruyne, S.
    Van Damme, N.
    Smeets, P.
    Ferdinande, L.
    Ceelen, W.
    Mertens, J.
    Van de Wiele, C.
    Troisi, R.
    Libbrecht, L.
    Laurent, S.
    Geboes, K.
    Peeters, M.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (12) : 1926 - 1933
  • [3] Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
    S De Bruyne
    N Van Damme
    P Smeets
    L Ferdinande
    W Ceelen
    J Mertens
    C Van de Wiele
    R Troisi
    L Libbrecht
    S Laurent
    K Geboes
    M Peeters
    [J]. British Journal of Cancer, 2012, 106 : 1926 - 1933
  • [4] Noncompartmental Kinetic Analysis of DCE-MRI Data From Malignant Tumors: Application to Glioblastoma Treated With Bevacizumab
    Port, Ruediger E.
    Bernstein, Lisa J.
    Barboriak, Daniel P.
    Xu, Lu
    Roberts, Timothy P. L.
    van Bruggen, Nicholas
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2010, 64 (02) : 408 - 417
  • [5] GPU-Accelerated Compartmental Modeling Analysis of DCE-MRI Data from Glioblastoma Patients Treated with Bevacizumab
    Hsu, Yu-Han H.
    Huang, Ziyin
    Ferl, Gregory Z.
    Ng, Chee M.
    [J]. PLOS ONE, 2015, 10 (03):
  • [6] Chemotherapy response monitoring in colorectal liver metastases by DCE-MRI and FDG-PET
    Vriens, Dennis
    van Laarhoven, Hanneke
    van Asten, Jack
    Krabbe, Paul
    Visser, Eric
    Heerschap, Arend
    Punt, Cornelis
    de Geus-Oei, Lioe-Fee
    Oyen, Wim
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [7] Preoperative chemotherapy for colorectal liver metastases: prediction of response by DCE-MRI and FDG-PET/CT?
    De Bruyne, S.
    Smeets, P.
    Van Damme, N.
    Ceelen, W.
    Van de Wiele, C.
    Laurent, S.
    Geboes, K.
    Mertens, J.
    Peeters, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S195 - S195
  • [8] GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab
    Hsu, Yu-Han H.
    Ferl, Gregory Z.
    Ng, Chee M.
    [J]. MAGNETIC RESONANCE IMAGING, 2013, 31 (04) : 618 - 623
  • [9] Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis
    Hirashima, Yoshinori
    Yamada, Yasuhide
    Tateishi, Ukihide
    Kato, Ken
    Miyake, Mototaka
    Horita, Yosuke
    Akiyoshi, Kohei
    Takashima, Atsuo
    Okita, Natsuko
    Takahari, Daisuke
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Shirao, Kuniaki
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (10) : 2359 - 2365
  • [10] DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study
    Mross, Klaus
    Fasol, Ulrike
    Frost, Annette
    Benkelmann, Robin
    Kuhlmann, Jan
    Buechert, Martin
    Unger, Clemens
    Blum, Hubert
    Hennig, Juergen
    Milenkova, Tsveta P.
    Tessier, Jean
    Krebs, Annetta D.
    Ryan, Anderson J.
    Fischer, Richard
    [J]. VASCULAR CELL, 2009, 1